|
| ID |
DDInter1628 |
| Drug Type |
small molecule |
| Molecular Formula |
C17H18N6 |
| Molecular Weight |
306.373
|
| Description |
Ruxolitinib is a kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.
|
| ATC Classification |
L01XE18
|
| IUPAC Name |
(3R)-3-Cyclopentyl-3-(4-{7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl}-1H-Pyrazol-1-Yl)Propanenitrile |
| InChI |
Inchi=1S/C17H18N6/C18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/H6,8-12,15H,1-5H2,(H,19,20,21)/T15-/M1/S1 |
| InChI Key |
HFNKQEVNSGCOJV-OAHLLOKOSA-N |
| Canonical SMILES |
N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1 |
| Useful Links |
DrugBank
ChEMBL
PubChem
|